Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Blood (2024) 144 (Supplement 1): 773.

https://doi.org/10.1182/blood-2024-201057

Published: 2024

Journal Articles

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study

Blood (2024) 144 (Supplement 1): 770.

https://doi.org/10.1182/blood-2024-203818

Published: 2024

Journal Articles

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Elena Zamagni, Tobias Silzle, Ivan Špička, Sabrin Tahri, Sarah Lonergan, Inger S. Nijhof, Antonietta Pia Falcone, Evangelos Terpos, Jakub Radocha, Roberto Mina, Guldane Cengiz Seval, Meral Beksac, Cesar Rodriguez, Marcelo C. Pasquini, Michel Delforge, Vania Hungria, Donna Reece, Philippe Moreau, Yael C. Cohen, Kihyun Kim, Dominik Dytfeld, Jiří Minařík, Irene Strassl, Jelena Bila, Martin Schreder, Janusz Krawczyk, Fredrik Schjesvold, Caroline Cicin-Sain, Christoph Driessen, Gordon Cook, Lugui Qiu, Gonzalo Martin Garate, Agoston Gyula Szabo, Roman Hájek, Marc S. Raab, Silvia Mangiacavalli, Hermann Einsele, Andrew Spencer, Mario Boccadoro, Helen Vassalou, Lixia Pei, Yingqi Shi, Maria Krevvata, Ryan Gruber, Caline Sakabedoyan, Margaret Cobb, Jagoda Jasielec, Himal Amin, Rachel Kobos, Pieter Sonneveld, Niels W.C.J. van de Donk

Blood (2024) 144 (Supplement 1): 494.

https://doi.org/10.1182/blood-2024-205608

Published: 2024

Journal Articles

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide

Blood (2024) 144 (Supplement 1): 4731.

https://doi.org/10.1182/blood-2024-199282

Published: 2024

Journal Articles

Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network

Markus Rückert, Guillaume Azarias, Mamta Garg, Ceri Bygrave, Hannah Belcher, Clare Hague, Kristina Bardenheuer, Wout Vekemans, Morten Salomo, Blanca Gros Otero, Nolen Perualila, Michel Van Speybroeck, Joris Diels, Vladimir Maisnar, Ivan Špička, Roman Hájek

Blood (2024) 144 (Supplement 1): 2388.

https://doi.org/10.1182/blood-2024-201692

Published: 2024

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study

Blood (2024) 144 (Supplement 1): 3352.

https://doi.org/10.1182/blood-2024-207087

Published: 2024

Journal Articles

Risk Groups in Relapsed and Refractory Multiple Myeloma Treated By Lenalidomide Based Triplets - Analysis of the Czech Myeloma Group

Jiri Minarik, Luděk Pour, Tomas Jelinek, Ivan Spicka, Alexandra Jungova, Jakub Radocha, Petr Pavlicek, Tomas Pika, Stork Martin, Jan Straub, Vojtech Latal, Dominik Fric, Vladimir Maisnar, Roman Hajek

Blood (2024) 144 (Supplement 1): 2378.

https://doi.org/10.1182/blood-2024-200014

Published: 2024

Journal Articles

Teclistamab in Relapsed and Refractory Multiple Myeloma Patients - Czech Multi-Center Real World Evidence Analysis

Martin Stork, Jakub Radocha, Tomas Jelinek, Ivan Spicka, Tomas Pika, Alexandra Jungova, Jan Straub, Jiri Minarik, Ivanna Boichuk, Dominik Fric, Denisa Novakova, Tereza Popkova, Lenka Polcerova, Vladimir Maisnar, Ludek Pour, Roman Hajek

Blood (2024) 144 (Supplement 1): 5156.

https://doi.org/10.1182/blood-2024-202002

Published: 2024

Journal Articles

The Impact of Isatuximab Regimens on Hypogammaglobulinemia Occurrence, Recovery, and Associated Infections in Patients with Relapsed/Refractory Multiple Myeloma

Cesar Rodriguez, Aurore Perrot, Paul G. Richardson, Thierry Facon, Ivan Spicka, Albert Oriol, Kenshi Suzuki, Edvan Crusoe, Ajai Chari, Nicole Armstrong, Christina Tekle, Marie-Laure Risse, Thomas Martin, Philippe Moreau

Blood (2023) 142 (Supplement 1): 1980.

https://doi.org/10.1182/blood-2023-179925

Published: 2023

Journal Articles

Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Blood (2023) 142 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2023-177945

Published: 2023

Journal Articles

Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

Blood (2023) 142 (Supplement 1): 3383.

https://doi.org/10.1182/blood-2023-186997

Published: 2023

Journal Articles

Comparison of Lenalidomide Based Triplets (IRD, KRD and DRD) in Relapsed and Refractory Multiple Myeloma in Routine Practice

Jiri Minarik, Ludek Pour, Tomas Jelinek, Ivan Spicka, Alexandra Jungova, Jakub Radocha, Petr Pavlicek, Tomas Pika, Martin Stork, Jan Straub, Vladimir Maisnar, Roman Hajek

Blood (2023) 142 (Supplement 1): 4733.

https://doi.org/10.1182/blood-2023-179299

Published: 2023

Journal Articles

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

Blood (2023) 141 (6): 579–591.

https://doi.org/10.1182/blood.2022016782

Published: 2023

Includes: Supplemental data

Journal Articles

Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Subgroup Analysis By Number of Prior Lines of Treatment

Marcelo Capra, Thomas Martin, Philippe Moreau, Gracia Martinez, Albert Oriol, Youngil Koh, Hang Quach, Kwee Yong, Andreea Rawlings, Christina Tekle, Sandrine Macé, Marie-Laure Risse, Ivan Spicka

Blood (2022) 140 (Supplement 1): 7138–7140.

https://doi.org/10.1182/blood-2022-162731

Published: 2022

Journal Articles

Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies

Paul G. Richardson, Aurore Perrot, Jesús San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A. Dimopoulos, Jeffrey SY Huang, Jiri Minarik, Michele Cavo, H. Miles Prince, Sandrine Macé, Laure Malinge, Franck Dubin, Mony Morisse, Kenneth C. Anderson

Blood (2022) 140 (Supplement 1): 608–610.

https://doi.org/10.1182/blood-2022-159710

Published: 2022

Journal Articles

Patient Characteristics and Survival Outcomes of Lenalidomide Exposed non- Refractory vs. Lenalidomide Refractory Multiple Myeloma Patients in the HONEUR Federated Data Network

Roman Hajek, Henrik Sliwka, Martin Stork, Ivan Spicka, Tomas Jelinek, Jakub Radocha, Alexandra Jungova, Jiri Minarik, Jan Soukup, Nolen Joy Perualila, Joris Diels, Michel van Speybroeck, Nichola Erler-Yates, João Mendes, Kai Strobel, Sébastien Wischlen, Maximilian Merz

Blood (2022) 140 (Supplement 1): 7200–7202.

https://doi.org/10.1182/blood-2022-159401

Published: 2022

Journal Articles

Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

Blood (2021) 138 (Supplement 1): 3793.

https://doi.org/10.1182/blood-2021-146003

Published: 2021

Journal Articles

Follow-up Analysis of Ixazomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Routine Clinical Practice

Blood (2021) 138 (Supplement 1): 2716.

https://doi.org/10.1182/blood-2021-148836

Published: 2021

Journal Articles

Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in Czech Republic

Tereza Popkova, Ludek Pour, Ivan Spicka, Jakub Radocha, Alexandra Jungova, Jiri Minarik, Tomas Jelinek, Petr Pavlicek, Marta Krejci, Jan Straub, Vladimir Maisnar, Tereza Dekojova, Tomas Pika, Jan Soukup, Lenka Capkova, Roman Hájek

Blood (2021) 138 (Supplement 1): 4894.

https://doi.org/10.1182/blood-2021-153978

Published: 2021

Journal Articles

OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM) - Renal Impairment (RI) Analysis

Tadeusz Robak, Sosana Delimpasi, Ludek Pour, Tamas Masszi, Ivan Spicka, Wojciech Legiec, Pieter Sonneveld, Marcus Thuresson, Kajsa Larsson, Johan Harmenberg, Fredrik H. Schjesvold

Blood (2021) 138 (Supplement 1): 4777.

https://doi.org/10.1182/blood-2021-146550

Published: 2021

NARROW

Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide

Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network

Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study

Risk Groups in Relapsed and Refractory Multiple Myeloma Treated By Lenalidomide Based Triplets - Analysis of the Czech Myeloma Group

Teclistamab in Relapsed and Refractory Multiple Myeloma Patients - Czech Multi-Center Real World Evidence Analysis

The Impact of Isatuximab Regimens on Hypogammaglobulinemia Occurrence, Recovery, and Associated Infections in Patients with Relapsed/Refractory Multiple Myeloma

Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

Comparison of Lenalidomide Based Triplets (IRD, KRD and DRD) in Relapsed and Refractory Multiple Myeloma in Routine Practice

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Subgroup Analysis By Number of Prior Lines of Treatment

Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies

Patient Characteristics and Survival Outcomes of Lenalidomide Exposed non- Refractory vs. Lenalidomide Refractory Multiple Myeloma Patients in the HONEUR Federated Data Network

Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

Follow-up Analysis of Ixazomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Routine Clinical Practice

Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in Czech Republic

OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM) - Renal Impairment (RI) Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only